Donation

Donate
Myeloma Minute
Series
The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1–3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1–3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

January 8, 2024
ASH
Sequential T-Cell Engagement for Myeloma (“STEM”) Trial: A Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy

The STEM Trial Phase II Study on Cevostamab Consolidation After BCMA CAR T-Cell Therapy 

January 8, 2024
ASH
BMS-986393 (CC-95266), a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)–Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

Updates in Myeloma Treatment: BMS-986393 CAR T-Cell Therapy Shows Promise in Phase I Study for Relapsed/Refractory Patients

January 8, 2024
ASH
2023 Top Research ASH Webinar banner

Top Myeloma Research at ASH 2023 from a Patient Perspective

January 4, 2024
ASH
Impact of Dexamethasone (Dex) Dose Strength on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM): A Secondary Analysis of SWOG Studies S0777 and S1211

Impact of Dexamethasone (Dex) Dose Strength on Newly Diagnosed Multiple Myeloma

January 4, 2024
ASH
Randomized Phase III Study of Pomalidomide Cyclophosphamide Dexamethasone (PCd) Versus Pomalidomide Dexamethasone (Pd) in Relapse or Refractory Myeloma: An Asian Myeloma Network (AMN) Study Presented at ASH 2023

Optimizing Myeloma Treatment: Pomalidomide-based Regimens Compared in Asian Myeloma Network (AMN) Study — a Phase III Analysis of PCd vs. Pd for Relapse or Refractory Myeloma (RRMM)

January 4, 2024
ASH
The IMF brings support group leaders from across the country to the annual ASH meeting

The IMF Brings Support Group Leaders to ASH

June 22, 2023
ASH
Dr. Grosicki abstract on MagnetisMM-5

Elranatamab in Combination with Daratumumab for Patients with Relapsed Refractory Multiple Myeloma: Phase 3 MagnetisMM-5

February 10, 2023
ASH
Dr. Terpos ASH abstract on Circulating Plasma Cells

Increased Levels of Circulating Plasma Cells in Patients with Newly Diagnosed Multiple Myeloma Are Independently Associated with Poor Prognosis

February 7, 2023
ASH
Dr. Kastritis ASH abstract on Real world outcomes with Selinexor

Real World Efficacy and Toxicity of Selinexor: Importance of Dose Intensity and Post Progression Outcomes

February 6, 2023
ASH
Dr. Suzanne Trudel ASH Abstract on Tocilizumab

Tocilizumab pre-treatment reduced cytokine release syndrome in relapsed/refractory multiple myeloma patients receiving cevostamab

February 3, 2023
ASH
Dr Shaji Kumar ASH abstract on the ASCENT trial

Fixed Duration Therapy with Dara-KRd for High Risk Smoldering Multiple Myeloma: ASCENT Trial

February 3, 2023
ASH

Give Where Most Needed

Learn More